These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39254698)

  • 21. Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure.
    Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Suarez MD; Misra PP; Soto C; Low PA
    Ann Neurol; 2021 Jun; 89(6):1212-1220. PubMed ID: 33881777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
    Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
    Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease.
    Wilms AE; de Boer I; Pelzer N; In't Veld SGJG; Middelkoop HAM; Teunissen CE; Terwindt GM
    J Neurol; 2024 Jul; 271(7):4138-4145. PubMed ID: 38581544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
    Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
    Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers.
    Mangesius S; Mariotto S; Ferrari S; Pereverzyev S; Lerchner H; Haider L; Gizewski ER; Wenning G; Seppi K; Reindl M; Poewe W
    Parkinsonism Relat Disord; 2020 Aug; 77():57-63. PubMed ID: 32622301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
    Huang SY; Chen SF; Cui M; Zhao M; Shen XN; Guo Y; Zhang YR; Zhang W; Wang HF; Huang YY; Cheng W; Zuo CT; Dong Q; Yu JT
    Mov Disord; 2023 Apr; 38(4):676-682. PubMed ID: 36781585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
    Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
    J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases.
    Park Y; Kc N; Paneque A; Cole PD
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
    Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
    Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain proteome profiling implicates the complement and coagulation cascade in multiple system atrophy brain pathology.
    Rydbirk R; Østergaard O; Folke J; Hempel C; DellaValle B; Andresen TL; Løkkegaard A; Hejl AM; Bode M; Blaabjerg M; Møller M; Danielsen EH; Salvesen L; Starhof CC; Bech S; Winge K; Rungby J; Pakkenberg B; Brudek T; Olsen JV; Aznar S
    Cell Mol Life Sci; 2022 Jun; 79(6):336. PubMed ID: 35657417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy.
    van Ballegoij WJC; van de Stadt SIW; Huffnagel IC; Kemp S; Willemse EAJ; Teunissen CE; Engelen M
    Ann Clin Transl Neurol; 2020 Nov; 7(11):2127-2136. PubMed ID: 33047897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy.
    Zhang L; Cao B; Hou Y; Gu X; Wei Q; Ou R; Zhao B; Luo C; Shang H
    Mov Disord; 2022 Feb; 37(2):421-426. PubMed ID: 34719813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy.
    Tokutake T; Kasuga K; Tsukie T; Ishiguro T; Shimohata T; Onodera O; Ikeuchi T
    Parkinsonism Relat Disord; 2022 Sep; 102():30-35. PubMed ID: 35933820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL.
    Chen CH; Cheng YW; Chen YF; Tang SC; Jeng JS
    J Neuroinflammation; 2020 Apr; 17(1):124. PubMed ID: 32321529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.